Investigational seltorexant improved symptoms of major depressive disorder (MDD) and insomnia in people with an inadequate response to antidepressants, a phase III trial indicated. By week 6, the ...
The least-squares mean difference in the Hammersmith Functional Motor Scale-Expanded change from baseline at 12 months was 1.8 points for those 2 to 12 years receiving apitegromab vs placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback